Human Platelet Lysate Market Increasing Adoption in Cell Therapy

Introduction The global human platelet lysate (HPL) market is witnessing significant growth, driven by advancements in regenerative medicine, cell therapy, and tissue engineering. As a superior alternative to fetal bovine serum (FBS), human platelet lysate has gained traction due to its safety profile and efficiency in supporting cell growth and proliferation. Derived from human platelets, HPL is rich in growth factors and cytokines, making it an ideal supplement for cell culture applications. Between 2025 and 2032, the global human platelet lysate market is forecasted to expand at a CAGR of 3.4%, growing from $57.7 million to $72.5 million. Innovations in manufacturing processes, increasing demand for cell-based therapies, and the rising prevalence of chronic diseases are key factors propelling the market forward. As research institutions, biotechnology firms, and healthcare providers invest heavily in HPL-based solutions, the market is set for substantial expansion in th...